HCA Healthcare, Inc.

(New York Stock Exchange)
Back to all articles
Slightly Bullish +15

HCA Healthcare stock faces payer pressure ahead of 2027 outlook

Earnings report Guidance raised AI-generated analysis

πŸ“ˆ HCA Healthcare third-quarter revenue rose 3.6% to $19.849 billion despite challenging payer conditions.

πŸ“‰ Net income attributable to HCA fell 3.9% to $1.579 billion due to a $400 million hit from the shift of exchange customers to uninsured status.

πŸ₯ Same-facility equivalent admissions increased 3.0%, while emergency-room visits rose 5.1%, indicating resilient patient demand.

πŸ”» Elective care volume declined with same-facility inpatient surgeries down 1.4% and outpatient surgeries falling 3.7% year over year.

πŸ‘₯ The proportion of uninsured patients reached 10.5% of equivalent admissions, up from 8.5% a year earlier.

πŸ’° Management expects 2026 operating results to land in the upper half of guidance ranges for revenue and adjusted EBITDA.

πŸ“… CEO Sam Hazen projects 2027 volume growth of 2% to 3%, with detailed guidance expected in January.

⚠️ HCA anticipates a decline in Medicaid supplemental-payment net benefits of $550 million to $650 million in 2027.

πŸ›‘οΈ The company plans to rely on volume growth, cost initiatives, and technology investments to navigate payer pressures.

πŸ“ˆ Adjusted EBITDA grew 1.2% year over year to $3.918 billion, reflecting improved operating momentum.

Bullish Signals
  • HCA Healthcare reported a 3.6% increase in third-quarter revenue to $19.849 billion, demonstrating resilient patient demand.
  • Same-facility equivalent admissions rose 3.0% and emergency-room visits increased 5.1%, indicating strong underlying volume growth.
  • Adjusted EBITDA grew 1.2% year over year to $3.918 billion, showing improved operating momentum despite income declines.
  • Management raised confidence in the current year, expecting 2026 results to land in the upper half of previously issued guidance ranges.
  • CEO Sam Hazen projects volume growth of 2% to 3% for 2027, supported by resilient patient demand.
Risk Factors
  • Net income attributable to HCA fell 3.9% to $1.579 billion due to a $400 million reduction in pre-tax income from the shift of exchange customers to uninsured status.
  • Elective care volume declined significantly, with same-facility inpatient surgeries down 1.4% and outpatient surgeries falling 3.7% year over year.
  • The proportion of uninsured patients increased to 10.5% of equivalent admissions, up from 8.5% a year earlier, reflecting ongoing exchange coverage losses.
  • Management expects Medicaid supplemental-payment net benefits to decline by $550 million to $650 million in 2027 due to lower payments and policy conditions.
  • The shift toward uninsured patients is expected to weigh on growth, with a return to longer-term growth dependent on a better payer mix.
Full Analysis
HCA Healthcare reported third-quarter results ended September 30, 2026, showing resilient patient demand but significant headwinds from payer mix shifts. Revenue increased 3.6% to $19.849 billion, driven by strong volume growth in same-facility admissions and emergency room visits. However, net income attributable to the company fell 3.9% to $1.579 billion as the shift of former exchange customers to uninsured status reduced pre-tax income by approximately $400 million. The company's financial performance was further impacted by a decline in elective care, with same-facility inpatient surgeries dropping 1.4% and outpatient surgeries falling 3.7% compared to the prior-year quarter. Uninsured patients now represent 10.5% of equivalent admissions, up from 8.5% a year earlier, reflecting the ongoing challenge of exchange coverage losses. Management noted that while exchange equivalent admissions declined 19% year over year, they improved 8% from the second quarter. Looking ahead to 2027, HCA Healthcare expects earnings to remain generally consistent with 2026 levels despite continued pressure from Medicaid payment declines and payer mix issues. CEO Sam Hazen anticipates volume growth of 2% to 3% for the year, though he warns that a meaningful payer-mix effect will persist. The company plans to provide detailed 2027 guidance in January following the fourth-quarter report and the conclusion of the open enrollment period. Management is relying on volume growth, cost initiatives, and technology investments to offset the expected decline in Medicaid supplemental-payment net benefits of $550 million to $650 million in 2027. The company expects fewer people to lose exchange coverage than in 2026, but a better payer mix and stable policy conditions remain prerequisites for a return to longer-term growth. HCA Healthcare stock traded at 423.30 euros on November 2, 2026.